WEREWOLF THERAPEUTICS, INC. Increase (Decrease) in Accounts Payable, Trade
WEREWOLF THERAPEUTICS, INC. (HOWL) reported Increase (Decrease) in Accounts Payable, Trade of $241.00 thousand for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableTrade · last filed 2023-11-14
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2023-09-30 was -$104.00K.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2023-06-30 was -$616.00K, a 176.43% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2023-03-31 was $961.00K.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for the quarter ending 2022-12-31 was -$105.00K, a 116.13% decline year-over-year.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2022 was -$883.00K, a 187.69% decline from fiscal 2021.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2021 was $1.01M, a 159.54% increase from fiscal 2020.
- WEREWOLF THERAPEUTICS, INC. increase (decrease) in accounts payable, trade for fiscal 2020 was $388.00K.
| Period end | Increase (Decrease) in Accounts Payable, Trade 3 month | Increase (Decrease) in Accounts Payable, Trade 6 month | Increase (Decrease) in Accounts Payable, Trade 9 month | Increase (Decrease) in Accounts Payable, Trade 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$104.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$720.00K derived: sum of 2 quarters · filed 2023-11-14 | $241.00K 10-Q · filed 2023-11-14 | $136.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-06-30 | -$616.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $345.00K 10-Q · filed 2023-08-10 | $240.00K derived: sum of 3 quarters · filed 2023-08-10 | -$670.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2023-03-31 | $961.00K 10-Q · filed 2023-05-11 | $856.00K derived: sum of 2 quarters · filed 2023-05-11 | -$54.00K derived: sum of 3 quarters · filed 2023-11-14 | $752.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-12-31 | -$105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$1.01M derived: sum of 2 quarters · filed 2023-11-14 | -$209.00K derived: sum of 3 quarters · filed 2023-11-14 | -$883.00K 10-K · filed 2023-03-23 |
| 2022-09-30 | -$910.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$104.00K derived: sum of 2 quarters · filed 2023-11-14 | -$778.00K 10-Q · filed 2023-11-14 | -$127.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $806.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $132.00K 10-Q · filed 2023-08-10 | $783.00K derived: sum of 3 quarters · filed 2023-08-10 | -$725.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$674.00K 10-Q · filed 2023-05-11 | -$23.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.53M derived: sum of 3 quarters · filed 2023-05-11 | -$391.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$857.00K derived: sum of 2 quarters · filed 2023-03-23 | $283.00K derived: sum of 3 quarters · filed 2023-03-23 | $1.01M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$1.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$368.00K derived: sum of 2 quarters · filed 2022-11-10 | $356.00K 10-Q · filed 2022-11-10 | -$184.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.86M 10-Q · filed 2022-08-11 | $1.32M derived: sum of 3 quarters · filed 2022-08-11 | $1.67M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $724.00K 10-Q · filed 2022-05-10 | $184.00K derived: sum of 2 quarters · filed 2022-05-10 | $534.00K derived: sum of 3 quarters · filed 2022-05-10 | $810.00K derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | -$540.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-24 | -$190.00K derived: sum of 2 quarters · filed 2022-03-24 | $86.00K derived: sum of 3 quarters · filed 2022-03-24 | $388.00K 10-K · filed 2022-03-24 |
| 2020-09-30 | $350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $626.00K derived: sum of 2 quarters · filed 2021-11-10 | $928.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $276.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $578.00K 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $302.00K 10-Q · filed 2021-06-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |